Abstract

Background: Guselkumab is an IL-23 inhibitor approved for the treatment of moderate to severe plaque psoriasis (PsO). Little is known about the impact of guselkumab on patient-reported outcomes (PROs) in a real-world setting.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.